^
Association details:
| Biomarker: | PD-L1 overexpression + LAG3 expression + CTAG1B expression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | PD1 inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Tumor LAG-3 and NY-ESO-1 expression predict durable clinical benefits of immune checkpoint inhibitors in advanced non-small cell lung cancer
Published date:
01/17/2021
Excerpt:
NY-ESO-1 or LAG-3 expression was detected in all tumor samples from patients with high PD-L1 expression and was significantly associated with favorable outcomes...Patients with NSCLC who co-express NY-ESO-1 or LAG-3 with PD-L1 exhibit greater DCBs and improved long-term survival following anti-PD-1 therapy.
DOI:
10.1111/1759-7714.13834
